共 38 条
[22]
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
[J].
ANNALS OF THE RHEUMATIC DISEASES,
2017, 76 (01)
:79-87
[23]
Mechanisms of Disease: Psoriasis.
[J].
NEW ENGLAND JOURNAL OF MEDICINE,
2009, 361 (05)
:496-509
[24]
Genetics of psoriatic arthritis
[J].
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY,
2014, 28 (05)
:673-685
[28]
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
[J].
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY,
2017, 76 (03)
:418-431